HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

被引:187
作者
Ortiz, GM [1 ]
Nixon, DF [1 ]
Trkola, A [1 ]
Binley, J [1 ]
Jin, X [1 ]
Bonhoeffer, S [1 ]
Kuebler, PJ [1 ]
Donahoe, SM [1 ]
Demoitie, MA [1 ]
Kakimoto, WM [1 ]
Ketas, T [1 ]
Clas, B [1 ]
Heymann, JJ [1 ]
Zhang, LQ [1 ]
Cao, YZ [1 ]
Hurley, A [1 ]
Moore, JP [1 ]
Ho, DD [1 ]
Markowitz, M [1 ]
机构
[1] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA
关键词
D O I
10.1172/JCI7371
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Therapeutic intervention with highly active antiretroviral therapy (HAART) can lead to suppression of HIV-1 plasma viremia to undetectable levels for 3 or more years. However, adherence to complex drug regimens can prove problematic, and subjects may temporarily discontinue HAART for variable periods. We studied 6 HIV-1-infected individuals who stopped therapy. Off HAART, levels of viremia were suppressed to fewer than 500 copies/mL in 2 subjects for more than 12 and more than 24 months, respectively, and in I subject for 4 months on 1 occasion. Three subjects failed to contain plasma viremia. Broad and strong HIV-1-specific immune responses were detected in subjects with prolonged suppression of viral replication. This longitudinal study suggests that containment of HIV-1 replication to low or undetectable levels after discontinuation of HAART is associated with strong virus-specific immune responses. Boosting of HIV-1-specific immune responses should be considered as an adjunctive treatment strategy for HIV-1-infected individuals on HAART.
引用
收藏
页码:R13 / R18
页数:6
相关论文
共 32 条
  • [1] Antiretroviral therapy in countries with low health expenditure
    Arya, SC
    [J]. LANCET, 1998, 351 (9113) : 1433 - 1434
  • [2] Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
    Borrow, P
    Lewicki, H
    Wei, XP
    Horwitz, MS
    Peffer, N
    Meyers, H
    Nelson, JA
    Gairin, JE
    Hahn, BH
    Oldstone, MBA
    Shaw, GM
    [J]. NATURE MEDICINE, 1997, 3 (02) : 205 - 211
  • [3] VIRUS-SPECIFIC CD8+ CYTOTOXIC T-LYMPHOCYTE ACTIVITY ASSOCIATED WITH CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    BORROW, P
    LEWICKI, H
    HAHN, BH
    SHAW, GM
    OLDSTONE, MBA
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (09) : 6103 - 6110
  • [4] RETRACTED: Characterization of long-term survivors of human immunodeficiency virus type 1 infection (Retracted article. See vol 64, U5, 1998)
    Cao, YZ
    Qin, LM
    Zhang, LQ
    Safrit, J
    Ho, DD
    [J]. IMMUNOLOGY LETTERS, 1996, 51 (1-2) : 7 - 13
  • [5] Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
    Chun, TW
    Stuyver, L
    Mizell, SB
    Ehler, LA
    Mican, JAM
    Baseler, M
    Lloyd, AL
    Nowak, MA
    Fauci, AS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (24) : 13193 - 13197
  • [6] Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
    Connor, RI
    Korber, BTM
    Graham, BS
    Hahn, BH
    Ho, DD
    Walker, BD
    Neumann, AU
    Vermund, SH
    Mestecky, J
    Jackson, S
    Fenamore, E
    Cao, Y
    Gao, F
    Kalams, S
    Kunstman, KJ
    McDonald, D
    McWilliams, N
    Trkola, A
    Moore, JP
    Wolinsky, SM
    [J]. JOURNAL OF VIROLOGY, 1998, 72 (02) : 1552 - 1576
  • [7] Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
    Finzi, D
    Blankson, J
    Siliciano, JD
    Margolick, JB
    Chadwick, K
    Pierson, T
    Smith, K
    Lisziewicz, J
    Lori, F
    Flexner, C
    Quinn, TC
    Chaisson, RE
    Rosenberg, E
    Walker, B
    Gange, S
    Gallant, J
    Siliciano, RF
    [J]. NATURE MEDICINE, 1999, 5 (05) : 512 - 517
  • [8] Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
    Finzi, D
    Hermankova, M
    Pierson, T
    Carruth, LM
    Buck, C
    Chaisson, RE
    Quinn, TC
    Chadwick, K
    Margolick, J
    Brookmeyer, R
    Gallant, J
    Markowitz, M
    Ho, DD
    Richman, DD
    Siliciano, RF
    [J]. SCIENCE, 1997, 278 (5341) : 1295 - 1300
  • [9] Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
    Furtado, MR
    Callaway, DS
    Phair, JP
    Kunstman, KJ
    Stanton, JL
    Macken, CA
    Perelson, AS
    Wolinsky, SM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (21) : 1614 - 1622
  • [10] Gray CM, 1999, J IMMUNOL, V162, P1780